Physician profile
Anna C Freitag
NPI 1235113507
$13,025.88
in general payments reported to CMS, 2019-2025
33 companies · $1,892 in 2025
The $1,892 reported for 2025 was more than what 75% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,738 · 2020: $1,394 · 2021: $835 · 2022: $1,147 · 2023: $1,510 · 2024: $1,510 · 2025: $1,892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,846 · Gift: $59.40 · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,845.64 |
| Gift | $59.40 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $3,775.94 | 2019-2025 | Korlym |
| Novo Nordisk INC | $2,181.63 | 2019-2025 | Ozempic, Wegovy |
| Lilly USA, LLC | $1,244.60 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,129.02 | 2019-2025 | Jardiance |
| Valeritas, INC. | $798.72 | 2019 | |
| Abbott Laboratories | $700.78 | 2020-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals Lp | $658.91 | 2019-2024 | Farxiga, Lokelma |
| Xeris Pharmaceuticals, INC. | $369.09 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Amgen INC. | $361.48 | 2019-2025 | Tepezza, Evenity, Prolia |
| Abbvie INC. | $345.02 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $177.20 | 2019 | |
| Insulet Corporation | $139.44 | 2019-2025 | Omnipod |
| Medtronic, INC. | $110.33 | 2023-2025 | Minimed 780g |
| Mannkind Corporation | $107.99 | 2023 | Afrezza |
| Astellas Pharma US INC | $94.41 | 2024-2025 | Veozah |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $87.52 | 2025 | |
| Zealand Pharma US, INC. | $78.18 | 2020 | |
| Tandem Diabetes Care, INC. | $76.77 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Antares Pharma, INC. | $76.36 | 2024-2025 | Xyosted |
| Medtronic Minimed, INC. | $58.31 | 2019-2020 | |
| Averitas Pharma INC. | $56.97 | 2023-2025 | Qutenza |
| Recordati_rare_diseases_inc. | $47.48 | 2025 | Isturisa |
| Novartis Pharmaceuticals Corporation | $45.60 | 2025 | |
| Dexcom, INC. | $43.99 | 2024 | Dexcom G6 Transmitter |
| Almatica Pharma LLC | $42.74 | 2025 | Teriparatide |
| Intra-Sana Laboratories | $37.61 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Glaxosmithkline, LLC. | $30.09 | 2025 | Shingrix |
| Madrigal Pharmaceuticals | $29.05 | 2025 | Rezdiffra |
| Amneal Pharmaceuticals LLC | $27.12 | 2025 | Unithroid |
| Ascendis Pharma Endocrinology INC | $24.88 | 2025 | Yorvipath |
| Cequr Corporation | $24.50 | 2023 | Cequr Simplicity |
| Esperion Therapeutics, INC. | $23.78 | 2023 | Nexletol |
| Sanofi-Aventis U.S. LLC | $20.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Freitag listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.